Methylene Blue (Methylthioninium Chloride)

Methylthioninium Chloride acts as an electron carrier that reduces methemoglobin back to functional hemoglobin. It also inhibits nitric oxide synthase and guanylate cyclase, decreasing nitric oxide production and helping restore normal vascular tone and oxygen delivery.

The specific dose of Methylene Blue is determined by the prescribing clinician based on the patient’s condition, weight, and severity of toxicity. Dosing regimens are individualized and should follow established clinical guidelines and the product’s prescribing information.

The safety of Methylene Blue in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Methylene Blue is the first‑line antidote for methemoglobinemia, offering rapid reduction of methemoglobin levels. Alternative agents such as ascorbic acid are less potent and slower. Compared with newer experimental compounds, Methylene Blue has a well‑established safety profile and extensive clinical experience.

Methylene Blue should be stored at 2‑8 °C, kept refrigerated, protected from light, and not frozen or shaken. Maintaining the cold chain preserves its stability and efficacy for intravenous administration.

Methylene Blue is supplied as an intravenous solution and is administered directly into a vein by a qualified healthcare professional. The infusion rate and total volume are determined by the prescriber according to the clinical indication and patient response.

Serious risks include hemolysis in individuals with G6PD deficiency, severe allergic reactions such as anaphylaxis, paradoxical worsening of methemoglobinemia, and serotonin syndrome when combined with serotonergic medications. Prompt recognition and management of these events are essential.

Methylene Blue should be avoided in patients with known G6PD deficiency, those taking serotonergic drugs without careful monitoring, and individuals with a history of severe allergic reactions to the product. Contraindications must be evaluated by the treating clinician before administration.